This study aims to explore new treatments for Rheumatoid Arthritis (RA), a disease that causes joint pain and swelling. The study compares two types of medications: non-TNF biologics and tsDMARDs. Non-TNF biologics include drugs like rituximab, while tsDMARDs are newer medications including tofacitinib. The goal is to see which works better for people who still have active RA despite using a TNFi-biologic, a type of medicine that helps with inflammation.

**Key Points:**

• This study will last for up to 3 months with regular check-ups.
• It is important to have insurance that covers at least one drug from each treatment group.
• Participants can continue certain existing RA medications during the study.

To join, participants must have active RA and have used a TNFi-biologic for at least 3 months. They cannot have used more than three biologics or have certain health conditions like untreated infections or heart problems. This study is important because it may help improve treatment options for RA patients.